Login to Your Account



'Clear efficacy signal' sends Vitae soaring on psoriasis results

By Jennifer Boggs
Managing Editor

Thursday, March 17, 2016

When Vitae Pharmaceuticals Inc. called a halt to enrollment in its phase IIa trial testing VTP-43742 in psoriasis with no explanation, investors naturally feared the worst, sending shares plummeting to a 52-week low earlier this month.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription